Edesa Biotech, Inc.

NASDAQ:EDSA

Biotechnology

Healthcare
$5.75 +1.31%

+$0.09 today

Market cap
$55.39M
Beta
1.07
P/E (TTM)
-5.5
EPS (TTM)
-$1.27
52W Low $0.72High $20.32

Volume 0.07M

Average 0.62M

EDSA Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Edesa Biotech, Inc.NASDAQ: EDSA

Net Change in Cash · Q2 FY2026 · quarter ended Mar 2026

Net change in cash turns negative

Q2 FY2026 net change in cash was -$2.05M, compared with $12.33M a year earlier. Trailing-twelve-month net change in cash was -$3.89M.

Context

  • Net change in cash increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly net change in cash holds near -$2.05M or moves back toward the trailing-twelve-month quarterly average of -$973.24K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.05M-262.6% QoQ
Last fiscal yearSep 2025
$9.75M+325.6% YoY
LTMMar 2026
-$3.89M-135.1% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-116.6%——
1 year+325.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
9.75M USD
Year-over-year change
+325.6%
4-year CAGR
+98.7%

Net Change in Cash vs competitors

How EDSA compares with its peers on the latest reported figures

  • EDSA's LTM Mar 2026 net change in cash of $3.89M is the smallest of the 2 companies compared; the peer median is $4.31M.
  • Its year-over-year change of -135.1% is the lowest of 2, against a peer median of -128.4%.
EDSA Competitors Peer median
Net Change in Cash for EDSA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DWTXDogwood Therapeutics, Inc.LTM Mar 2026$4.31M -128.4%+6.1%—
EDSAEdesa Biotech, Inc.LTM Mar 2026$3.89M -135.1%——
Peer median (excluding EDSA) $4.31M-128.4%+6.1%—

Competitors are the stored peer set for EDSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income(13.34M)(17.55M)(8.37M)(6.17M)(7.19M)
Depreciation & Amortization118.79K118.19K183.47K186.05K119.27K
Deferred Income Tax(3.31M)(2.38M)(308K)00
Stock-Based Compensation3.2M2.26M1.25M537.49K729.64K
Change in Working Capital(3.64M)2.89M308K571.07K(985.65K)
Accounts Receivables(3.23M)2.03B562.77K356.34K(377.99K)
Inventory00000
Accounts Payables(124.72K)882.84K(556.27K)00
Other Working Capital(281.36K)(2.03B)301.5K214.73K(607.67K)
Other Non-Cash Items3.31M2.38M308K(14.77K)0
Operating Cash Flow(13.66M)(12.28M)(6.64M)(4.89M)(7.32M)
Capital Expenditures(6.15K)(5.66K)300
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00(3)00
Investing Cash Flow(6.15K)(5.66K)000
Debt Repayment000(29.53K)0
Common Stock Issued14.17M11.63M4.83M621.56K17.03M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow14.17M11.63M4.83M592.03K17.03M
Effect of Forex Changes121.9K(93.01K)76.85K(25.9K)46.22K
Net Change in Cash625.56K(748.34K)(1.73M)(4.32M)9.75M
Free Cash Flow(13.67M)(12.28M)(6.64M)(4.89M)(7.32M)

Edesa Biotech, Inc.

NASDAQ:EDSA

Intrinsic Alpha fair value

Locked

Current Price

$5.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.